An allograft inflammatory factor 1 (AIF1) single nucleotide polymorphism (SNP) is associated with anticentromere antibody positive systemic sclerosis

Rheumatology

Volumn 46, Issue 8, 2007, Pages 1248-1251

  Alkassab, Firas ^a   Gourh, P ^a   Tan, F K ^a   McNearney, T ^b   Fischbach, M ^c   Ahn, C ^a   Arnett, F C ^a   Mayes, M D ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

AIF1; Allograft inflammatory factor 1; Anticentromere antibodies; Autoantibodies; Genetics; Scleroderma; Systemic sclerosis

Indexed keywords

ALLOGRAFT INFLAMMATORY FACTOR 1; AUTOANTIBODY; CENTROMERE ANTIBODY; DNA TOPOISOMERASE;

AFRICAN AMERICAN; ARTICLE; CASE CONTROL STUDY; CAUCASIAN; CONTROLLED STUDY; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HISPANIC; HUMAN; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC SCLEROSIS;

ANTIBODIES, ANTINUCLEAR; CENTROMERE; DNA-BINDING PROTEINS; EPIDEMIOLOGIC METHODS; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; SCLERODERMA, SYSTEMIC; UNITED STATES;

EID: 34547830804     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem057     Document Type: Article

References (25)

1. Deininger MH, Meyermann R, Schluesener HJ. The allograft inflammatory factor-1 family of proteins. FEBS Lett 2002;514:115-21.
2. Autieri MV, Kelemen SE, Thomas BA, Feller ED, Goldman BI, Eisen HJ. Allograft inflammatory factor-1 expression correlates with cardiac rejection and development of cardiac allograft vasculopathy. Circulation 2002;106:2218-23.
3. Autieri MV, Carbone CM. Overexpression of allograft inflammatory factor-1 promotes proliferation of vascular smooth muscle cells by cell cycle deregulation. Arterioscler Thromb Vasc Biol 2001;21:1421-6.
4. Autieri MV, Chen X. The ability of AIF-1 to activate human vascular smooth muscle cells is lost by mutations in the EF-hand calcium-binding region. Exp Cell Res 2005;307:204-11.
5. Yang ZF, Ho DW, Lau CK et al. Allograft inflammatory factor-1 (AIF-1) is crucial for the survival and pro-inflammatory activity of macrophages. Int Immunol 2005;17:1391-7.
6. Tian Y, Kelemen SE, Autieri MV. Inhibition of AIF-1 expression by constitutive siRNA expression reduces macrophage migration, proliferation, and signal transduction initiated by atherogenic stimuli. Am J Physiol Cell Physiol 2006;290:C1083-91.
7. Kelemen SE, Autieri MV. Expression of allograft inflammatory factor-1 in T lymphocytes: A role in T-lymphocyte activation and proliferative arteriopathies. Am J Pathol 2005;167:619-26.
8. Negakawa Y, Nomoto S, Kato Y et al. Over-expression of AIF-1 in liver allografts and peripheral blood correlates with acute rejection after transplantation in rats. Am J Transplant 2004;4:1949-57.
9. Tan FK, Zhou X, Mayes MD et al. Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology 2006;45:694-702.
10. Gardner H, Shearstone J, Bandaru R et al. Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. Arthritis Rheum 2006;54:1961-73.
11. Tan FK, Hildebrand BA, Laester MS et al. Classification analysis of the transcriptosome of nonlesional cultured dermal fibroblasts from systemic sclerosis patients with early disease. Arthritis Rheum 2005;52:865-76.
12. Del Galdo F, Maul GG, Jimenez SA, Artlett CM. Expression of Allograft Inflammatory Factor 1 in tissues from patients with systemic sclerosis and in vitro differential experssion of its isoforms in response to Transforming Growth Factor b. Arthritis Rheum 2006;54:2616-25.
13. Artlett C, Otieno FG, Cane J, Jimenez S. Allograft Inflammatory Factor 1 gene polymorphisms and tissue expression in Systemic Sclerosis. Arthritis Rheum 2004;50:s440.
14. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
15. Arnett FC, Reveille JD, Goldstein R et al. Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis. Arthritis Rheum 1996;39:1151-60.
16. Reveille JD, Fischbach M, McNeamey T of at Systemic sclerosis in 3 UI ethnic groups: A comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum 2001;30:332-46.
17. Reveille JD, Durban E, MacLeod-St Clair MJ et al. Association of amino acid sequences in the HLA-DQB1 first domain with antitopoisomerase I autoantibody response in scleroderma (progressive systemic sclerosis). J Clin Invest 1992;90:973-80.
18. Reveille JD, Owerbach D, Goldstein R, Moreda R, Isern RA, Arnett FC. Association of polar amino acids at position 26 of the HLA-DQB1 first domain with the anticentromere autoantibody response in systemic sclerosis (scleroderma). J Clin Invest 1992;89:1208-13.
19. Assassi S, Tan FK. Genetics of scleroderma: Update on single nucleotide polymorphism analysis and microarrays. Curr Opin Rhuematol 2005;17:761-7.
20. Reveille JD, Durban E, Goldstein R, Moreda R, Arnett FC. Racial differences in the frequencies of scleroderma-related autoantibodies. Arthritis Rheum 1992;35:216-8.
21. Henikoff Ng. Accounting for human polymorphisms predicted to affect protein function. Genome Res 2002;12:436-46.
22. Cepeda EJ, Reveille JD. Autoantibodies in systemic sclerosis and fibrosing syndromes: Clinical indications and relevance. Curr Opin Rheumatol 2004;16:723-32.
23. Prescott RJ, Freemont AJ, Jones CJ, Hoyland J, Fielding P. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 1992;166:255-63.
24. Sgonc R, Gruschwitz MS, Dietrich H, Recheis H, Gershwin ME, Wick G. Endothelial call apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 1996;98:785-92.
25. Ahmed SS, Tan FK, Arnett FC, Jin L, Geng YJ. Induction of apoptosis and fibrillin 1 expression in human dermal endothelial cells by scleroderma sera containing anti-endothelial cell antibodies. Arthritis Rheum 2006;54:2250-62.